Free tool
FAERS Monitor: Gilotrif
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201292 or its brand name (Gilotrif, Afatinib Dimaleate). Reports on generic versions are filed under their own applications.
Reports
6,622
Serious
5,732
87% of reports
Hospitalization
2,095
Death reported
1,475
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea2,128
- malignant neoplasm progression1,696
- rash884
- death524
- nausea488
- stomatitis486
- decreased appetite450
- vomiting410
- paronychia355
- dehydration317
- fatigue292
- off label use283
- metastases to central nervous system270
- asthenia238
- drug ineffective234
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 5 |
| 2013 | 122 |
| 2014 | 503 |
| 2015 | 744 |
| 2016 | 794 |
| 2017 | 731 |
| 2018 | 936 |
| 2019 | 645 |
| 2020 | 582 |
| 2021 | 456 |
| 2022 | 343 |
| 2023 | 283 |
| 2024 | 214 |
| 2025 | 161 |
| 2026 | 103 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,537 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| paronychiaSignal | 355 | 279.0 | 251.0 | 90,169 |
| metastases to central nervous systemSignal | 270 | 67.9 | 60.3 | 17,367 |
| malignant neoplasm progressionSignal | 1,696 | 53.5 | 51.3 | 86,247 |
| stomatitisSignal | 486 | 25.6 | 23.5 | 11,428 |
| diarrhoeaSignal | 2,128 | 10.5 | 10.1 | 18,803 |
| dehydrationSignal | 317 | 7.6 | 6.8 | 1,806 |
| rashSignal | 884 | 6.5 | 6.1 | 4,145 |
| decreased appetiteSignal | 450 | 6.2 | 5.6 | 1,959 |
| vomitingSignal | 410 | 2.8 | 2.5 | 473 |
| astheniaSignal | 238 | 2.0 | 1.8 | 122 |
| nausea | 488 | 2.0 | 1.8 | 237 |
| death | 524 | 1.9 | 1.8 | 245 |
| fatigue | 292 | 1.2 | 1.1 | 9 |
| off label use | 283 | 1.0 | 0.9 | 0 |
| drug ineffective | 234 | 0.6 | 0.5 | 84 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.